GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagenic Therapeutics Inc (STU:MBP) » Definitions » Short Percentage of Float

Protagenic Therapeutics (STU:MBP) Short Percentage of Float


View and export this data going back to 2021. Start your Free Trial

What is Protagenic Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Protagenic Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, Protagenic Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Protagenic Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Protagenic Therapeutics's Short Percentage of Float falls into.


Protagenic Therapeutics (STU:MBP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagenic Therapeutics Inc (STU:MBP) » Definitions » Short Percentage of Float
Comparable Companies
PCSA THER MYMD ENZN SCPX AZTR XBIO NLSP SNGX CELZ OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
PTIX:USA
Address
149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Website
https://www.protagenic.com
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Protagenic Therapeutics (STU:MBP) Headlines

No Headlines